Journal of Otology & RhinologyISSN: 2324-8785

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
bahis siteleri bahis siteleri bahis siteleri casino siteleri

Research Article, J Otol Rhinol Vol: 3 Issue: 4

Efficacy and Safety of Sequential Chemoradiation with Docetaxel, Cisplatin, and 5-Fluorouracil (TPF) in Treating the Patients with Squamous Cell Carcinoma of the Hypopharynx: A Phase II Clinical Trial

Niloofar Ahmadloo1, Sayed Hasan Hamedi2, Samira Razzaghi2, Bijan Khademi3,4, Seyed Basir Hashemi4, Leila Moaddabshoar2, Ahmad Mosalaei1,3, Mansour Ansari1, Shapour Omidvari1,Hamid Nasrolahi1 and Mohammad Mohammadianpanah5*
1Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2Student Research Committee, Department of Radiation Oncology, Shiraz University of Medical Sciences, Shiraz, Iran
3Shiraz institute for Cancer Research, Shiraz University of Medical Sciences,Shiraz, Iran
4Department of Otolaryngology, Head and Neck Surgery, Khalili Hospital,Shiraz University of Medical Sciences, Shiraz, Iran
5Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz,Iran
Corresponding author : Mohammad Mohammadianpanah
Colorectal Research Center, Department of Radiation Oncology, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz 71936-11351, Iran
Tel: 0098-711-6125170; Fax: 0098-711-6474320
E-mail: mohpanah@gmail.com
Received: April 07, 2014 Accepted: June 03, 2014 Published: June 15, 2014
Citation: Ahmadloo N, Hamedi SH, Razzaghi S, Khademi B, Hashemi SB (2014) Efficacy and Safety of Sequential Chemoradiation with Docetaxel, Cisplatin, and 5-Fluorouracil (TPF) in Treating the Patients with Squamous Cell Carcinoma of the Hypopharynx: A Phase II Clinical Trial. J Otol Rhinol 3:4. doi:10.4172/2324-8785.1000160

Abstract

Efficacy and Safety of Sequential Chemoradiation with Docetaxel, Cisplatin, and 5-Fluorouracil (TPF) in Treating the Patients with Squamous Cell Carcinoma of the Hypopharynx: A Phase II Clinical Trial

Background: The present study aimed to investigate the efficacy and safety of sequential chemoradiation with docetaxel, cisplatin, and 5-Fluorouracil (TPF) in the patients with Squamous Cell Carcinoma (SCC) of the hypopharynx.

Patients and Methods: In this single arm phase II clinical trial, eligible patients had to have newly diagnosed, locally advanced (T3-T4 and/or N2-N3, M0) hypopharyngeal SCC, no prior therapy, Eastern Cooperative Oncology Group performance scale ≤1, and normal or acceptable organ function. The patients were assigned to receive three cycles of 3-weekly induction chemotherapy in an outpatient setting with docetaxel 75 mg/m2, cisplatin 75 mg/m2, and 5-fluorouracil 750 mg/m2 × 3 days of 8-hour infusion, followed by definite radiotherapy with a total dose of 70 Gy with concurrent cisplatin 30 mg/m2 weekly. Tumor response rates and treatmentrelated toxicity were the primary and secondary study endpoints, respectively.

Keywords: Locally advanced hypopharyngeal cancer; Induction chemotherapy; Docetaxel; Cisplatin; 5-Fluorouracil; TPF regimen; Chemoradiation

international publisher, scitechnol, subscription journals, subscription, international, publisher, science

Track Your Manuscript

Awards Nomination

Media Partners

Associations

open access